Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Patients with cancer are increasingly being treated with drugs designed to modulate the
response of their immune system, broadly to boost their body's defences against cancer.
However, there is an unmet need to identify which patients are unlikely to benefit. Deciding
on benefit from therapy uses standard imaging methods (e.g. CT scans), which can take time
(months) whereas DNA in the bloodstream could be measured more rapidly.
The main aim of this study is to assess whether changes in the level of circulating tumour
DNA (ctDNA) can quickly determine a patients response. This would enable patients to change
therapies more quickly if they are not responding and reduce exposure to unnecessary side
effects.